P1.09-29 in Situ Growth Pattern in Lung Adenocarcinoma Is Divisible Into Distinct Categories With Divergent Biological and Survival Implications

Journal of Thoracic Oncology - United States
doi 10.1016/j.jtho.2018.08.805
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

P1.09-27 Clear Cell Adenocarcinoma Subtype Is an Independent Predictor of Better Survival in Patients With Lung Adenocarcinoma

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

SCD1 Is Associated With Tumor Promotion, Late Stage and Poor Survival in Lung Adenocarcinoma

Oncotarget
Oncology
2016English

A Multigene Assay Is Prognostic of Survival in Patients With Early-Stage Lung Adenocarcinoma

Clinical Cancer Research
Cancer ResearchOncology
2008English

P2.03-29 Prognostic Significance of Phosphorylated Fyn in Patients With Lung Adenocarcinoma

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Expression of CLDN1 and CLDN10 in Lung Adenocarcinoma in Situ and Invasive Lepidic Predominant Adenocarcinoma

Journal of Cardiothoracic Surgery
CardiologyCardiovascular MedicineMedicinePulmonaryRespiratory MedicineSurgery
2013English

P1.01-29 Crizotinib in Advanced Lung Adenocarcinoma Patients With ALK or ROS-1 Rearrangement: Is It the Same?

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P1.09-16 Novel Somatic Gene Mutation of SLC17A9, Detected in Early-Stage Lung Adenocarcinoma

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Overexpression of ANLN in Lung Adenocarcinoma Is Associated With Metastasis

Thoracic Cancer
MedicinePulmonaryRespiratory MedicineOncology
2019English

Mesothelin Overexpression Is a Marker of Tumor Aggressiveness and Is Associated With Reduced Recurrence-Free and Overall Survival in Early-Stage Lung Adenocarcinoma

Clinical Cancer Research
Cancer ResearchOncology
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy